Portal de Periódicos da CAPES

Treatment of spinocerebellar ataxia with buspirone

2007; Elsevier BV; Volume: 260; Issue: 1-2 Linguagem: Inglês

10.1016/j.jns.2007.04.019

1878-5883

Mitra Assadi, Joseph V. Campellone, Christopher G. Janson, J. Jon Veloski, Robert J. Schwartzman, Paola Leone,

Parkinson's Disease Mechanisms and Treatments

Preliminary data suggest potential benefit of 5-HT receptor agonists in the treatment of ataxias. We studied the effects of buspirone in a cohort of twenty patients with spinocerebellar ataxia (SCA). Twenty patients were treated in this double-blind, placebo controlled, cross-over trial with either buspirone HCl 30 mg twice daily or placebo for 3 months. Buspirone was not shown to be superior to placebo in the treatment of patients with SCA.